A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)

Eisai

Status: Completed

Conditions: Parkinson Disease

Treatments: Drug: Equfina

Study type: Observational

Funder types: Industry

Identifiers

NCT04724109

EQF01S

Details and patient eligibility

About

The purpose of the study is to investigate the incidences of psychiatric symptoms (example, hallucinations), somnolence and sudden onset of sleep, dyskinesia, and retinal degeneration-related events during treatment with Equfina in participants with parkinson's disease (including participants with hepatic impairment).

Enrollment: 1,088 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Participants with Parkinson's disease, who are naïve to Equfina

Exclusion criteria

1. Participants previously treated with Equfina
2. Participants who have contraindications on package insert of Equfina

Trial design

1,088 participants in 1 patient group

Equfina

Description:

Participants with parkinson's disease will be administered Equfina 50 milligram (mg) tablets, orally, once daily in combination with levodopa-containing products. On the basis of symptoms, Equfina 100 mg tablet, orally, once daily may be selected for participants. All the participants will be observed for up to 24 weeks prospectively.

Treatment:

Drug: Equfina